TruBridge Stock Plummets as Accounting Errors Spark Investor Lawsuits

TruBridge Stock Plummets as Accounting Errors Spark Investor Lawsuits

2026-06-22 companies

New York, Tuesday, 23 June 2026.
TruBridge Inc. (NASDAQ: TBRG) faces a storm of legal and financial turmoil after revealing accounting errors in revenue recognition and financial statements for 2023–2025. The stock crashed 10.5% in a single day, nearing a 52-week low of $14.78—down from a high of $29.78. Multiple law firms, including Rosen Law Firm, are investigating potential securities fraud, raising alarms about corporate transparency. With restatements pending and a merger deal under scrutiny, investors are left questioning the company’s future amid intensifying regulatory scrutiny in the healthcare IT sector.

The Accounting Errors That Shook Investor Confidence

TruBridge Inc. (NASDAQ: TBRG) disclosed on 17 March 2026 that it had identified ‘out-of-period errors’ in its previously issued financial statements, spanning fiscal years 2023 and 2024, as well as the first three quarters of 2025 [1][2]. The errors, which the company attributed to miscalculations in revenue recognition, stock-based compensation, and capitalized software development expenses, triggered an immediate regulatory and investor backlash. The admission came as TruBridge filed a Notification of Late Filing on Form 12b-25, citing the need to complete ‘certain related analyses’ before submitting its 2025 Annual Report [1]. The company’s stock price reacted sharply, plunging $1.84 per share on 17 March 2026—a single-day decline of -10.46%—to close at $15.75 [1][3]. By 24 March 2026, the stock had fallen further to $14.78, nearing its 52-week low of $14.63 and marking a stark contrast to its 52-week high of $29.78 [3].

The financial restatements and delayed filings prompted a flurry of securities fraud investigations, with at least five prominent law firms—including Rosen Law Firm, Glancy Prongay Wolke & Rotter LLP, Ademi LLP, Law Offices of Howard G. Smith, and The Schall Law Firm—announcing probes into potential violations of federal securities laws [3][4]. These investigations center on allegations that TruBridge and its executives may have misled investors by overstating the company’s financial performance or failing to disclose material risks in a timely manner. Rosen Law Firm, which is leading one of the most high-profile inquiries, has urged shareholders who purchased TruBridge stock between 17 March 2023 and 16 March 2026 to come forward, signaling the potential for a class-action lawsuit [1]. The law firm’s involvement underscores the severity of the allegations, as Rosen Law Firm is recognized for its expertise in securities litigation, having secured billions in settlements for investors in similar cases [GPT].

Financial Metrics Under Scrutiny: What the Errors Reveal

The accounting errors cast doubt on TruBridge’s previously reported financial metrics, which had painted a picture of robust growth. For fiscal year 2024, the company had reported a year-over-year net income growth of 55.4%, while trailing twelve-month (TTM) revenue growth stood at 0.9% [3]. However, these figures are now subject to revision pending the restatement of financials. The company’s TTM net margin was reported at 1.6%, with earnings per share (EPS) at $0.39, though these numbers may also be adjusted [3]. Valuation metrics, such as the price-to-earnings (P/E) ratio of 38.37, price-to-sales (P/S) ratio of 0.63, and price-to-free-cash-flow (P/FCF) ratio of 7.54, were calculated using the flawed financial data and are likely to shift significantly once restatements are finalized [3]. The errors raise broader questions about TruBridge’s internal controls and governance, particularly as the company operates in the highly regulated healthcare IT sector, where financial transparency is critical for maintaining trust with clients, regulators, and investors [GPT].

A Merger Deal Complicates the Crisis

Amid the accounting scandal, TruBridge’s proposed merger with Inventurus Knowledge Solutions, Inc. (IKS) has added another layer of complexity to the company’s challenges. The deal, announced earlier in 2026, values TruBridge at $26.25 per share in cash—a premium over its current trading price but still below its 52-week high [5]. However, the merger is now under scrutiny by Brodsky & Smith, a law firm investigating whether TruBridge’s board of directors breached its fiduciary duties by agreeing to the deal without ensuring full transparency about the company’s financial health [5]. Shareholders are being encouraged to contact the firm to assess whether the merger consideration is fair, given the recent revelations about accounting irregularities [5]. The investigation highlights the potential for conflicts of interest and the risks of entering into major corporate transactions while financial statements are under review.

Investor Uncertainty and the Path Forward

For TruBridge investors, the path forward is fraught with uncertainty. The company’s market capitalization has shrunk to $221.8 million, while its enterprise value stands at $388.7 million, reflecting a steep decline in investor confidence [6]. The free cash flow (FCF) yield, reported at 13.3% on a TTM basis, may also be revised downward once restatements are complete [6]. Analysts warn that the company could face significant financial penalties, costly settlements from class-action lawsuits, or even delisting from the NASDAQ if the accounting errors are deemed material [alert! ‘No official statement from NASDAQ regarding delisting as of 23 June 2026’]. However, there remains a possibility that the restatements will reveal less severe discrepancies than initially feared, allowing TruBridge to regain footing with improved internal controls and a clean bill of health from auditors [GPT]. The outcome of the merger investigation and the resolution of the securities fraud probes will be critical in determining whether the company can recover or if it will face further erosion of shareholder value.

Sources


securities litigation healthcare IT